Register
Community
Overview
Experts
Editors
Fellows
Code of conduct
Company
About Us
FAQs
Privacy Policy
Terms of Use
Careers
Programs
News
News Releases
Press Coverage
Publications
Blog
Contact Us
Sign in
Please select the option that best describes you:
Topics:
Internal Medicine
•
Allergy & Immunology
•
Drug Allergy
Do you believe that pretreatment with montelukast or other LTRAs can reduce the risk of urticaria or angioedema with NSAIDS?
Related Questions
Would you consider rechallenging immunotherapy if the first dose was accompanied with an acute infusion reaction with low back pain, shortness of breath and chest pain which resolved with monitoring, and subsequent cardiac workup being negative?
Do you perform patch testing with a history of SCAR with the goal of performing a drug challenge?
How do you manage an iodinated contrast allergy leading to grade 5 anaphylaxis in a patient who will foreseeably need another iodinated contrast agent in the future?
Do you utilize any desensitization protocols for delayed hypersensitivity reactions?
Are drug challenges after serum sickness-like reactions useful in delabeling the allergy?
Is omalizumab an option for a patient needing a specific antibiotic with an IgE-mediated reaction who continues to have reactions during a desensitization?
Are you using any AI models to de-label penicillin allergy?
Have you been able to safely use other bisphosphonates in patients who developed an allergic reaction (angioedema) to fosamax?
Do you recommend desensitization to biologics since this has to occur repeatedly?
How do you interpret high C1q binding assay with otherwise normal C1q, C3, C4, CH50 in a patient with recurrent urticaria with positive ANA at high titer 1:1280, negative dsDNA, RNP, SM, normal CBC, CMP, UA, and UPCR.
